Nature Reviews Gastroenterology & Hepatology

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	964
Zolbetuximab treatment in metastatic gastric cancer	686
Hybrid EASL Congress 2023	640
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	629
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	553
Mapping neuroimmune interactions in the gut	548
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	497
2023 FDA approvals in gastroenterology and hepatology	490
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	433
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	426
Western lifestyle, metaflammation and the cell of origin of colon cancer	343
Nomenclature of HBV core protein-targeting antivirals	322
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	297
Advancing nutrition science for global health	294
The future of treating pancreatic exocrine insufficiency	271
Digestive Disease Week 2022	266
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health	260
Black–White disparities across the colorectal cancer care continuum in the USA	249
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	238
Large language models for clinical decision support in gastroenterology and hepatology	233
Artificial intelligence and automation in endoscopy and surgery	219
New understanding of hepatobiliary MRI	214
Metastatic pancreatic cancer and the liver	210
Lessons from incretin-based therapy in MASH and obesity	202
Inflammatory bowel disease in pregnancy and breastfeeding	196

A crucial Fusobacterium nucleatum clade in colorectal cancer	195
Novel insights into chronic HBV infection	183
Food as medicine in gastrointestinal cancer therapy	182
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease	179
The critical role of gut–brain signalling in eating behaviour and obesity	173
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	171
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	168
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	168
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	165
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	156
Integrated systems approach to identify environmental factors in intestinal inflammation	155
Characterizing the genomic landscape of colorectal cancer	152
Implications of the evolving knowledge of the genetic architecture of MASLD	152
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment	141
Estimating dietary intake from human stool DNA	141
HDCA ameliorates NAFLD in mice	135
Probiotics for preterms: sharing complex decision-making	134
The path to successful hepatitis C elimination in Spain	132
Preventing the progression of cirrhosis to decompensation and death	128
Medical therapy of paediatric inflammatory bowel disease	127
Metabolic diseases in the East Asian populations	124
Human intestinal B cells in inflammatory diseases	119
SSRIs and depression: role of gut–brain communication	113
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	106
Current and future colorectal cancer screening strategies	103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease	99
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	98
Proteases in intestinal health and disease	93
Liver, ageing and disease	91
ECCO’24	88
Phase III results for first-line treatment for metastatic colorectal cancer	88
NAFLD prevalence in older patients with T2DM	88
GLP1R agonists in NAFLD: a promising therapy on the horizon	82
Microbiota and colorectal cancer — controlling for confounders challenges associations	82
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	80
Enteric nervous system transfers stress to the gut	79
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	77
Author Correction: Hepatic immune regulation and sex disparities	71
The future of pathology in gastroenterology and hepatology	69
Transforming the landscape of liver cancer detection and care	65
HIV-associated gut microbiome influences gut mucosal immunity	64
Hepatic glucose metabolism in the steatotic liver	64
Hepatic inflammatory responses in liver fibrosis	64
Artificial intelligence in liver cancer — new tools for research and patient management	62
SMART cancer risk prediction	61
Liver dialysis in ACLF	60
International collaborative research to improve gallbladder cancer prevention	60
Gut bacteria go on record	60
AI predicts pancreatic cancer risk	60
Nifty new tools for microbiome treatment design	58

A new era in obesity management	57
A neurobiotic sense curbs feeding: a new frontier in gut–brain communication	55
MASLD as a non-communicable disease	54
Nutrient sensing and small intestinal enteric neurons	53
Elucidating the transmission landscape of the human microbiome	52
Pushing the frontier of gut microbiome health cross-kingdom and cross-organ	51
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	50
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	50
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	49
Hepatitis E virus: from innate sensing to adaptive immune responses	48
Tirzepatide to treat obesity: phase III results	47
A novel pathomics signature for gastric cancer	47
Cathepsin S in liver fibrogenesis	46
The steatotic liver disease burden paradox: unravelling the key role of alcohol	45
Cellular and molecular basis of proximal small intestine disorders	45
Microplastics, nanoplastics and liver disease: an emerging health concern?	45
Antibiotic-perturbed microbiota and the role of probiotics	44
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	44
Therapeutic landscape and future direction of metastatic colorectal cancer	43
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	43
Classifying compounds as prebiotics — scientific perspectives and recommendations	43
Commensal fungi in intestinal health and disease	42
Bridging the gap: increasing MENA representation in MASLD clinical trials	41
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	41
Author Correction: Improving IBD outcomes in the era of many treatment options	40
Long-term normothermic liver perfusion	40
Author Correction: Current and future colorectal cancer screening strategies	39
Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease	39
Reply to ‘The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view’	39
Diet-driven microbiome restoration associated with cardiometabolic benefits	38
Changes in cholera burden across Africa	38
Justice, equity, diversity and inclusion in gastroenterology and hepatology	37
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	36
Alcohol-free and low-strength drinks: friend or foe?	36
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	35
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	35
A Roadmap for the Human Gut Cell Atlas	34
Gut virome dynamics: from commensal to critical player in health and disease	31
Public health policies to prevent alcohol-related liver disease	31
Resmetirom safe for nonalcoholic fatty liver disease	30
New target and timing in PDAC immunotherapy?	30
ECCO’25	30
Global epidemiology of cirrhosis — aetiology, trends and predictions	30
Digestive Disease Week 2023	29
Elafibranor in primary biliary cholangitis	29
Deciphering potential implications of dietary microplastics for human health	27
Envisioning how to advance the MASH field	27
Digestive Disease Week 2025	26
Intermittent fasting for NASH and HCC in mice	26
A resource for the food microbiome and its links with the human microbiome	25
Microplastics and nanoplastics in the human gut: from signals to standards	25
Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment	24
Positive longer-term results for efruxifermin in MASH	23
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	22
Food inequity and insecurity and MASLD: burden, challenges, and interventions	22
Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment	22
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	21
Nanoparticles in NAFLD therapeutics	21
Cholangiocarcinoma 2026: status quo, unmet needs and priorities	21
HCV direct-acting antiviral therapy adherence in people who inject drugs	21
IL-17A-producing CD8+ T cells in pancreatic cancer	20
Human liver tissue in a mouse host	20
Optimizing sacral nerve stimulation to relieve chronic constipation	20
Follow-up of SER-109 for recurrent C. difficile	20
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	20
Gastrointestinal health and the environment: a bidirectional relationship	19
Amitriptyline as second-line treatment for IBS in primary care settings	19
Predicting mortality in cirrhosis	19
Liquid biopsy combined with machine learning predicts early detection in liver disease	18
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	17
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	17
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	16
Lactylation and HCC progression	16
Combination treatment further extends survival	15
Maintaining remission in ulcerative colitis	15
Elucidating the nutrient preferences of mouse gut bacteria	15
Neoadjuvant chemotherapy for operable colon cancer	14
Biologic agents for IBD come of age as host–microbe interactions emerge	14
‘Dark matter’ beyond the bacteria in faecal microbiota transplantation	13
Liver steatosis and fibrosis in China	13

Elucidating the link between clonal haematopoiesis and chronic liver disease	13
AI-enabled ‘endo-histo-omics’: breaking down intestinal barriers in IBD	12
Mucus secretion from colonic goblet cells is regulated by autophagy and ER stress	12
Mapping the malignant transformation from polyps to CRC	12
Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	12
Positioning therapies for the management of inflammatory bowel disease	11
Fermented foods and gastrointestinal health: underlying mechanisms	11
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions	11
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards	11
Host–pathobiont interactions in Crohn’s disease	10
Cellular triads in T cell liver tumours	10
A bloody disgrace — time to change patient safety culture	10
Actions of thyroid hormones and thyromimetics on the liver	10
Redefining cancer care: the case for an onco-gastroenterology subspecialty	10
Liquid biopsy guides anti-EGFR rechallenge in metastatic CRC	10
Paracellular permeability and tight junction regulation in gut health and disease	10
Liver transplantation plus chemotherapy improved survival in patients with colorectal liver metastasis	10
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	9
Rethinking gastric cancer prevention through an immigrant health lens	9
Metabotherapy for intestinal disease: using metabolites to prevent and treat disorders of the gut	9
Next-generation enteric neuroscience — fostering the future of the field	9
The war on pancreatic cancer: progress and promise	9
Sex bias in clinical trials in gastroenterology and hepatology	9
Mechanisms of metastatic colorectal cancer	8
Connecting with the community	8
Precision models in hepatocellular carcinoma	8
An expert panel Consensus Statement on ALD without experts by experience	8
CXCR2 inhibition in NASH-HCC	8
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease	8
Liraglutide treatment in children with obesity	8
Defining ‘gut health’: a leap forward, but still some road to travel	8
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management	7
The appendix and ulcerative colitis — an unsolved connection	7
NAFLD, MAFLD and obesity: brothers in arms?	7
Human hepatocyte organoids model early NAFLD	7
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal	7
Potassium-competitive acid blockers for the management of gastroesophageal reflux disease	7
Dietary guidelines for gastrointestinal disorders: key to optimizing practice but more work needed	7
Rome Foundation Working Team Report on overlap in disorders of gut–brain interaction	7
Rhythmicity of infant microbiota and dietary effects	7
Artificial intelligence in inflammatory bowel disease: bridging innovation, implementation and impact	7
Stigma: a major barrier to hepatitis B elimination	7
Understanding the therapeutic toolkit for inflammatory bowel disease	7
The 3 Ps of IBD today — prevention, pre-diagnosis and participation	7
Effect of bariatric surgery on risk of oesophagogastric cancer	7
Metabolic health across the ages: how microbiota members support our well-being	6
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	6
Colonoscopy screening and risk of CRC	6
Fetal liver development and implications for liver disease pathogenesis	6
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	6
What do we mean by gut health?	6
Combination therapy with methotrexate in paediatric Crohn’s disease	6
Pouchitis: pathophysiology and management	6
WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials	6
Contrasting aspects of human excreta	6
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	6
Novel interventions against alcohol-related liver disease	5
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons	5
Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms	5
Liver fibrosis with methotrexate — an overestimated risk?	5
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	5
Benign liver tumours: understanding molecular physiology to adapt clinical management	5
The microbiome regulates host metabolic health and diseases through microbial enzymes	5
Metastasis and pericytes in oesophageal cancer	5
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	5
Physical activity and the gut	5
Beyond preservation: future machine perfusion for liver assessment and repair	5
Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC	4
Development of MKK4 inhibitors for liver regeneration	4
CIDEB variants protect against liver disease	4
Diagnosing paediatric coeliac disease	4
Fazirsiran shows promise for liver disease in AAT	4
The metabolic nature of inflammatory bowel diseases	4
Reduction in colorectal cancer incidence by screening endoscopy	4
Mechanisms and pathophysiology of Barrett oesophagus	4
Women in endoscopy: leading the way	4
A link to the past	4
Congenital diarrhoea and enteropathy genetics	4
A prime role for PIEZO2 in DRG neurons in mechanosensation in the gut	4
The global burden of inflammatory bowel disease: from 2025 to 2045	4
MASH-induced senescence and liver cancer	4
Advances in liver and pancreas organoids: how far we have come and where we go next	4
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	4
Investigating two versus three doses of mRNA vaccine in patients with cirrhosis	4
Ultra-processed diet increases CRC risk	4
Upadacitinib therapy for Crohn’s disease	4
Role of intestinal B cells in NASH and liver fibrosis	4
Therapeutic developments in pancreatic cancer	4
Fresh perspectives on how to build, maintain and repair the ENS	3
Dietary management of adults with IBD — the emerging role of dietary therapy	3
Colonization of the inflamed intestine by an oral bacterium	3
Perianal fistula surgical closure in Crohn’s disease	3
Liver preserved ex situ for 3 days transplanted into patient	3
Microbial signatures in pancreatic cancer	3
Next generation of gastrointestinal electrophysiology devices	3